Monitor for COVID-19 vaccine resistance evolution during clinical trials

David A. Kennedy; Andrew F. Read; David A. Kennedy

doi:10.1371/journal.pbio.3001000

Monitor for COVID-19 vaccine resistance evolution during clinical trials

David A. Kennedy, Andrew F. Read, David A. Kennedy

Research output: Contribution to journal › Article › peer-review

35 Citations (SciVal)

Abstract

Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-Term impact of COVID-19 vaccines.

Original language	English (US)
Article number	e3001000
Journal	PLoS biology
Volume	18
Issue number	11
DOIs	https://doi.org/10.1371/journal.pbio.3001000
State	Published - Nov 9 2020

All Science Journal Classification (ASJC) codes

Neuroscience(all)
Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)
Agricultural and Biological Sciences(all)

Access to Document

10.1371/journal.pbio.3001000

Cite this

@article{dd8c49111d8140bd907cfc61ebb3360d,

title = "Monitor for COVID-19 vaccine resistance evolution during clinical trials",

abstract = "Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-Term impact of COVID-19 vaccines.",

author = "Kennedy, {David A.} and Read, {Andrew F.} and Kennedy, {David A.}",

note = "Publisher Copyright: {\textcopyright} 2020 Kennedy, Read.",

year = "2020",

month = nov,

day = "9",

doi = "10.1371/journal.pbio.3001000",

language = "English (US)",

volume = "18",

journal = "PLoS Biology",

issn = "1544-9173",

publisher = "Public Library of Science",

number = "11",

}

TY - JOUR

T1 - Monitor for COVID-19 vaccine resistance evolution during clinical trials

AU - Kennedy, David A.

AU - Read, Andrew F.

AU - Kennedy, David A.

PY - 2020/11/9

Y1 - 2020/11/9

N2 - Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-Term impact of COVID-19 vaccines.

AB - Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-Term impact of COVID-19 vaccines.

UR - http://www.scopus.com/inward/record.url?scp=85096148960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096148960&partnerID=8YFLogxK

U2 - 10.1371/journal.pbio.3001000

DO - 10.1371/journal.pbio.3001000

M3 - Article

C2 - 33166303

AN - SCOPUS:85096148960

SN - 1544-9173

VL - 18

JO - PLoS Biology

JF - PLoS Biology

IS - 11

M1 - e3001000

ER -

Monitor for COVID-19 vaccine resistance evolution during clinical trials

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this